Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page
- Check3 days agoChange DetectedNapoli, Campania, Italy, 80131 was renamed to Naples, Campania, Italy, 80131 and a Naples listing was added, with the page revision updated to v3.5.0.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded Revision: v3.4.3; removed Revision: v3.4.2.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check40 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2. This appears to be a version control update with no visible changes to study information or page layout.SummaryDifference0.0%

- Check47 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. This appears to be a minor technical update without changes to the study content or user-facing features.SummaryDifference0.0%

- Check61 days agoChange DetectedAdded a Show glossary option and updated the page revision to v3.4.0. Capitalization and wording were updated for 'No FEAR Act Data' and 'Last Update Submitted that Met QC Criteria' (replacing the previous 'Last Update Submitted that met QC Criteria').SummaryDifference0.1%

- Check68 days agoChange DetectedRevision label on the page changed from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.